Cardio Ed

The LAAOS III was published in June 2021. The trial tested that if, on a background of anticoagulation, surgical left atrial appendage occlusion during cardiac surgery was beneficial or not. Do watch/ listen.

SGLT2 inhibitors are the new drugs which have been approved for heart failure with reduced ejection fraction (HFrEF). After the landmark EMPA-REG_OUTCOME, DECLARE TIMI 58, EMPEROR REDUCED and DAPA HF trials, empagliflozin and dapagliflozin have found a place in the management of HFrEF or heart failure. Lets discover what makes them special drugs in heart failure.

COVID-19 Vaccine Associated Thrombosis - What a medical practitioner should know? We have been listening about AstraZeneca vaccine associated thrombosis a lot. However, not much is known about this entity. I have tried to discuss Vaccine Associated Thrombosis in detail in this lecture. Do listen.

How to give anticoagulation in COVID-19 patients?

How to choose the right patient, and right drug?

How long to continue with anticoagulation in COVID19?

I try to answer these questions.

The presentation is not based on anecdotes/ experience.

There arent any trials i am discussing here.

Discussion strictly confined to International guidelines only.